Dosing and Re-Administration of Lentiviral Vector for In Vivo Gene Therapy in Rhesus Monkeys and ADA-Deficient Mice

Denise A. Carbonaro-Sarracino, Alice F. Tarantal, C. Chang I. Lee, Michael L. Kaufman, Stephen Wandro, Xiangyang Jin, Michele Martinez, Danielle N. Clark, Krista Chun, Colin Koziol, Cinnamon L. Hardee, Xiaoyan Wang, Donald B. Kohn

Research output: Contribution to journalArticle

Abstract

Adenosine deaminase (ADA)-deficient mice and healthy rhesus monkeys were studied to determine the impact of age at treatment, vector dosage, dosing schedule, repeat administration, biodistribution, and immunogenicity after systemic delivery of lentiviral vectors (LVs). In Ada−/− mice, neonatal treatment resulted in broad vector marking across all tissues analyzed, whereas adult treatment resulted in marking restricted to the liver, spleen, and bone marrow. Intravenous administration to infant rhesus monkeys also resulted in dose-dependent marking in the liver, spleen, and bone marrow. Using an ELISA to monitor anti-vector antibody development, Ada−/− neonatal mice did not produce an antibody response, whereas Ada−/− adult mice produced a strong antibody response to vector administration. In mice and monkeys with repeat administration of LV, a strong anti-vector antibody response was shown in response to the second LV administration, which resulted in LV inactivation. Three separate doses administered to immune competent mice resulted in acute toxicity. Pegylation of the vesicular stomatitis virus G protein (VSV-G)-enveloped LVs showed a less robust anti-vector response but did not prevent the inactivation of the second LV administration. These studies identify important factors to consider related to age and timing of administration when implementing systemic delivery of LVs as a potential therapeutic agent.

Original languageEnglish (US)
Pages (from-to)78-93
Number of pages16
JournalMolecular Therapy - Methods and Clinical Development
Volume16
DOIs
StatePublished - Mar 13 2020

Fingerprint

Macaca mulatta
Genetic Therapy
Antibody Formation
Anti-Idiotypic Antibodies
Spleen
Bone Marrow
Liver
Therapeutics
Intravenous Administration
Haplorhini
Appointments and Schedules
Enzyme-Linked Immunosorbent Assay
Mouse Ada protein

Keywords

  • ADA-deficiency
  • ERT
  • gene therapy
  • immune response
  • in vivo
  • lentiviral vector
  • repeat administration
  • rhesus monkeys

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Dosing and Re-Administration of Lentiviral Vector for In Vivo Gene Therapy in Rhesus Monkeys and ADA-Deficient Mice. / Carbonaro-Sarracino, Denise A.; Tarantal, Alice F.; Lee, C. Chang I.; Kaufman, Michael L.; Wandro, Stephen; Jin, Xiangyang; Martinez, Michele; Clark, Danielle N.; Chun, Krista; Koziol, Colin; Hardee, Cinnamon L.; Wang, Xiaoyan; Kohn, Donald B.

In: Molecular Therapy - Methods and Clinical Development, Vol. 16, 13.03.2020, p. 78-93.

Research output: Contribution to journalArticle

Carbonaro-Sarracino, DA, Tarantal, AF, Lee, CCI, Kaufman, ML, Wandro, S, Jin, X, Martinez, M, Clark, DN, Chun, K, Koziol, C, Hardee, CL, Wang, X & Kohn, DB 2020, 'Dosing and Re-Administration of Lentiviral Vector for In Vivo Gene Therapy in Rhesus Monkeys and ADA-Deficient Mice', Molecular Therapy - Methods and Clinical Development, vol. 16, pp. 78-93. https://doi.org/10.1016/j.omtm.2019.11.004
Carbonaro-Sarracino, Denise A. ; Tarantal, Alice F. ; Lee, C. Chang I. ; Kaufman, Michael L. ; Wandro, Stephen ; Jin, Xiangyang ; Martinez, Michele ; Clark, Danielle N. ; Chun, Krista ; Koziol, Colin ; Hardee, Cinnamon L. ; Wang, Xiaoyan ; Kohn, Donald B. / Dosing and Re-Administration of Lentiviral Vector for In Vivo Gene Therapy in Rhesus Monkeys and ADA-Deficient Mice. In: Molecular Therapy - Methods and Clinical Development. 2020 ; Vol. 16. pp. 78-93.
@article{993d1c5e68f74866925f36bd7dfd7d15,
title = "Dosing and Re-Administration of Lentiviral Vector for In Vivo Gene Therapy in Rhesus Monkeys and ADA-Deficient Mice",
abstract = "Adenosine deaminase (ADA)-deficient mice and healthy rhesus monkeys were studied to determine the impact of age at treatment, vector dosage, dosing schedule, repeat administration, biodistribution, and immunogenicity after systemic delivery of lentiviral vectors (LVs). In Ada−/− mice, neonatal treatment resulted in broad vector marking across all tissues analyzed, whereas adult treatment resulted in marking restricted to the liver, spleen, and bone marrow. Intravenous administration to infant rhesus monkeys also resulted in dose-dependent marking in the liver, spleen, and bone marrow. Using an ELISA to monitor anti-vector antibody development, Ada−/− neonatal mice did not produce an antibody response, whereas Ada−/− adult mice produced a strong antibody response to vector administration. In mice and monkeys with repeat administration of LV, a strong anti-vector antibody response was shown in response to the second LV administration, which resulted in LV inactivation. Three separate doses administered to immune competent mice resulted in acute toxicity. Pegylation of the vesicular stomatitis virus G protein (VSV-G)-enveloped LVs showed a less robust anti-vector response but did not prevent the inactivation of the second LV administration. These studies identify important factors to consider related to age and timing of administration when implementing systemic delivery of LVs as a potential therapeutic agent.",
keywords = "ADA-deficiency, ERT, gene therapy, immune response, in vivo, lentiviral vector, repeat administration, rhesus monkeys",
author = "Carbonaro-Sarracino, {Denise A.} and Tarantal, {Alice F.} and Lee, {C. Chang I.} and Kaufman, {Michael L.} and Stephen Wandro and Xiangyang Jin and Michele Martinez and Clark, {Danielle N.} and Krista Chun and Colin Koziol and Hardee, {Cinnamon L.} and Xiaoyan Wang and Kohn, {Donald B.}",
year = "2020",
month = "3",
day = "13",
doi = "10.1016/j.omtm.2019.11.004",
language = "English (US)",
volume = "16",
pages = "78--93",
journal = "Molecular Therapy - Methods and Clinical Development",
issn = "2329-0501",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Dosing and Re-Administration of Lentiviral Vector for In Vivo Gene Therapy in Rhesus Monkeys and ADA-Deficient Mice

AU - Carbonaro-Sarracino, Denise A.

AU - Tarantal, Alice F.

AU - Lee, C. Chang I.

AU - Kaufman, Michael L.

AU - Wandro, Stephen

AU - Jin, Xiangyang

AU - Martinez, Michele

AU - Clark, Danielle N.

AU - Chun, Krista

AU - Koziol, Colin

AU - Hardee, Cinnamon L.

AU - Wang, Xiaoyan

AU - Kohn, Donald B.

PY - 2020/3/13

Y1 - 2020/3/13

N2 - Adenosine deaminase (ADA)-deficient mice and healthy rhesus monkeys were studied to determine the impact of age at treatment, vector dosage, dosing schedule, repeat administration, biodistribution, and immunogenicity after systemic delivery of lentiviral vectors (LVs). In Ada−/− mice, neonatal treatment resulted in broad vector marking across all tissues analyzed, whereas adult treatment resulted in marking restricted to the liver, spleen, and bone marrow. Intravenous administration to infant rhesus monkeys also resulted in dose-dependent marking in the liver, spleen, and bone marrow. Using an ELISA to monitor anti-vector antibody development, Ada−/− neonatal mice did not produce an antibody response, whereas Ada−/− adult mice produced a strong antibody response to vector administration. In mice and monkeys with repeat administration of LV, a strong anti-vector antibody response was shown in response to the second LV administration, which resulted in LV inactivation. Three separate doses administered to immune competent mice resulted in acute toxicity. Pegylation of the vesicular stomatitis virus G protein (VSV-G)-enveloped LVs showed a less robust anti-vector response but did not prevent the inactivation of the second LV administration. These studies identify important factors to consider related to age and timing of administration when implementing systemic delivery of LVs as a potential therapeutic agent.

AB - Adenosine deaminase (ADA)-deficient mice and healthy rhesus monkeys were studied to determine the impact of age at treatment, vector dosage, dosing schedule, repeat administration, biodistribution, and immunogenicity after systemic delivery of lentiviral vectors (LVs). In Ada−/− mice, neonatal treatment resulted in broad vector marking across all tissues analyzed, whereas adult treatment resulted in marking restricted to the liver, spleen, and bone marrow. Intravenous administration to infant rhesus monkeys also resulted in dose-dependent marking in the liver, spleen, and bone marrow. Using an ELISA to monitor anti-vector antibody development, Ada−/− neonatal mice did not produce an antibody response, whereas Ada−/− adult mice produced a strong antibody response to vector administration. In mice and monkeys with repeat administration of LV, a strong anti-vector antibody response was shown in response to the second LV administration, which resulted in LV inactivation. Three separate doses administered to immune competent mice resulted in acute toxicity. Pegylation of the vesicular stomatitis virus G protein (VSV-G)-enveloped LVs showed a less robust anti-vector response but did not prevent the inactivation of the second LV administration. These studies identify important factors to consider related to age and timing of administration when implementing systemic delivery of LVs as a potential therapeutic agent.

KW - ADA-deficiency

KW - ERT

KW - gene therapy

KW - immune response

KW - in vivo

KW - lentiviral vector

KW - repeat administration

KW - rhesus monkeys

UR - http://www.scopus.com/inward/record.url?scp=85075627536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075627536&partnerID=8YFLogxK

U2 - 10.1016/j.omtm.2019.11.004

DO - 10.1016/j.omtm.2019.11.004

M3 - Article

AN - SCOPUS:85075627536

VL - 16

SP - 78

EP - 93

JO - Molecular Therapy - Methods and Clinical Development

JF - Molecular Therapy - Methods and Clinical Development

SN - 2329-0501

ER -